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Abstract
Background: To study the protein profile of the serum exosomes of patients with coronary artery an-
eurysms (CAA) caused by Kawasaki disease (KD). 
Methods: Two-dimensional electrophoresis (2-DE) was used to identify proteins from the exosomes 
of serum obtained from children with CAA caused by KD, as well as healthy controls. Differentially 
expressed proteins were identified using matrix-assisted laser desorption/ionization time-of-flight/time-
of-flight mass spectrometry (MALDI-TOF/TOF MS) analysis. 
Results: Thirty two differentially expressed proteins were identified (18 up-regulated and 14 down-
regulated) from serum exosomes of children with CAA and were compared to healthy controls. The 
expression levels of 4 proteins (TN, RBP4, LRG1, and APOA4) were validated using Western blotting. 
Classification analysis and protein–protein network analysis showed that they are associated with 
multiple functional groups, including host immune response, inflammation, apoptotic process, develop-
mental process, and biological adhesion process. 
Conclusions: These findings establish a comprehensive proteomic profile of serum exosomes from 
children with CAA caused by KD, and provide additional insights into the mechanisms of CAA caused 
by KD. (Cardiol J 2019; 26, 5: 584–593)
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Introduction
Kawasaki disease (KD) is the most prevalent 
inflammatory coronary artery disease with an un-
known etiology [1]. Eighty percent of patients are 
younger than 5 years old [2]. It is characterized 
by the development of coronary artery aneurysms 
(CAAs) [3]. CAAs may cause ruptures, thrombosis, 
stenosis, or myocardial ischemia if there is a failure 
or delay in treatment. It is therefore important to 
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make an accurate diagnosis and choose the appro-
priate therapy during early stages of the disease.
Several scoring systems have been established 
to identify the risk factors for CAA [4, 5]. Dura-
tion of fever has been reported as a potent risk 
factor. Male sex, younger patient age, and delayed 
diagnosis and treatment have also been found to be 
correlated with the development of CAA. Labora-
tory-detected indexes such as thrombocytopenia, 
leukocytosis, reduced hemoglobin, and reduced 
serum albumin are also prominent risk factors 
[6]. However, no specific laboratory test exists for 
CAA, and it is hard to establish a diagnosis, espe-
cially in early stages. The methods for diagnosing 
CAA are primarily imaging systems such as echo-
cardiography [7], computed tomography (CT), and 
magnetic resonance imaging (MRI) [3]. However, 
these methods have a relatively low sensitivity. 
The incidence of CAA has decreased as a result 
of treatments with intravenous immunoglobulin 
(IVIG); however, up to 5% of treated patients still 
develop CAA compared to up to 25% of untreated 
patients [2]. Therefore, it is crucial to understand 
the molecular pathogenesis of CAA to improve 
diagnosis and therapy of CAA in patients with KD.
Exosomes, 30–100 nm membrane vesicles 
of endocytic origin that are secreted by most 
cell types, are important intercellular commu-
nicators [8, 9]. As exosomes can transmit many 
molecules intercellularly, they are considered 
a potential source of new biomarkers. Exosomes 
may act as mediators for the activation of signal-
ing mechanisms in the target cell, intercellular 
communication, transfer of proteins and miRNAs, 
or the disposal of cellular components [10]. Thus, 
exosomes carry physiological and pathological 
biomarker information, and changes in serum exo-
some protein composition may reflect the patho-
logical processes of systemic diseases. Proteomics 
analysis is currently considered to be a powerful 
tool for the global evaluation of protein expression 
and has been widely applied in studying biomarkers 
and the molecular pathogenesis of diseases [11]. 
In the current study, we employed two-dimen-
sional electrophoresis (2-DE) and matrix-assisted 
laser desorption ionization time-of-flight/time-of-
flight mass spectrometry (MALDI-TOF/TOF MS) 
to compare the proteomes of exosomes from serum 
samples collected from healthy children and from 
children with CAA caused by KD. Western blot-
ting was used to confirm the results of the 2-DE 
analysis. According to available research, this is 
the first study to perform a proteomic analysis 
in the context of pathogenesis of CAA caused by 
KD, providing a comprehensive atlas of the serum 
exosome proteome, and providing clues for further 
diagnostic and therapeutic strategies for CAA 
caused by KD. 
Methods
Preparation of serum samples
This study was approved by the Ethical Com-
mittee of Guangzhou Women and Children’s Medi-
cal Center (permit [2013]077); the legal guardians 
of all children enrolled in the study provided 
written informed consent. Blood samples from 
5 patients with CAA caused by KD were randomly 
recruited according to the criteria of the Ameri-
can Heart Association and the Japanese Ministry 
of Health and Welfare [12]. The diagnoses of all 
patients were validated by more than 2 pediatric 
cardiologists, and all other possible diseases were 
ruled out. Blood samples from 5 healthy children 
were used as a control group. Blood samples 
were separated by centrifugation at 1,000 × g for 
10 min. Serum aliquots were collected and stored at 
−80°C. The serum obtained was further processed 
for exosome isolation. 
Precipitation of serum exosomes
Exosomes were separated from the sera of all 
participants using ExoQuick precipitation (System 
Biosciences Inc., Palo Alto, CA, USA) according to 
the manufacturer instructions [13, 14].
Exosome characterization 
Serum exosomes were precipitated using the 
exosome extraction reagent. The extracts were 
centrifuged at 1,500 × g for 10 min at 4°C. The 
exosome pellet was suspended in phosphate-
buffered saline (PBS) in 4 × the volume of serum. 
A copper mesh was placed on a wax plate, then 
100 μL exosome suspension was added for 4 min. 
The copper mesh was removed and placed in 2% 
phosphotungstic acid for 5 min. The mesh was then 
laid on filter paper for drying. The morphological 
features of the exosomes were observed using 
transmission electron microscopy (TEM). 
Exosome characterization  
using Western blot analysis
The exosome pellet was dissolved in protein 
lysis buffer, and a Bradford protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA) was used 
to determine protein concentration. Samples 
were separated by one-dimensional (1-D) SDS- 
-PAGE, then transferred to a PVDF membrane. The 
586 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 5
membrane was incubated in anti-CD63 (1:1000), 
-HSP90a (1:1000), and -Flotillin (1:1000) antibo-
dies at 4°C overnight, followed by incubation with 
secondary antibodies at room temperature for 1 h. 
Specific protein bands were visualized using the 
SuperSignal enhanced chemiluminescence (ECL) 
system (Thermo Fisher Scientific, Waltham, MA, 
USA) and imaged on x-ray film. 
Protein extraction of serum exosome
The exosome samples were grouped into two 
pooled samples consisting of equal amounts of the 
5 experimental samples from each group (CAA 
and control groups) before proteomic analysis. 
The Bradford protein assay kit was subsequently 
used to determine the final protein concentration 
of the exosomes according to the manufacturer 
instructions.
2-DE
According to a protocol published previously 
[15], 2-DE analysis was performed with slight 
modifications. In brief, the prepared pooled protein 
samples (120 mg protein on analytical gels, or 
600 mg protein on preparative gels) were mixed with 
rehydration buffer to a volume of 450 μL. IPG strips 
(pH 4–7, 24 cm, GE Healthcare, Little Chalfont, 
UK) were used for the first dimension to isolate the 
altered proteins, and the following parameters were 
used: 20°C, 300 V for 30 min, 700 V for 30 min, 
1,500 V for 1.5 h, 9,900 V for 3 h, 9,900 V for 6.5 h, 
600 V for 20 h, 8,000 V constant for a total of 
56 000 Vh. After completion of the isoelectric fo-
cusing (IEF) program, the strips were equilibrated 
in two steps: 15 min in an IPG equilibration buffer 
(6 M urea, 2% SDS, 30% glycerol, 0.375M Tris, 
20 mg/mL DTT, and a trace of bromophenol blue), 
and then alkylated for 15 min. Subsequently, 
a 12.5% 2-D SDS-PAGE was performed. Elec-
trophoresis was carried out at 20 mA per gel for 
40 min and then at 30 mA per gel until the dye front 
reached the bottom. The protein spots were visu-
alized by either Coomassie Brilliant Blue G-250 
staining or silver staining.
Image analysis
The gels were analyzed using the Image-
Master 2D Platinum software (GE Healthcare). 
The normalized protein amount for each spot was 
calculated as the ratio of the volume on each spot 
to the total spot volume on the gel. Protein spots 
with significant differences in abundance (increase 
or decrease of > 1.5-fold) were selected for further 
analysis.
In-gel digestion
Differentially expressed protein spots were 
manually excised from the 2-DE gels. Each gel 
piece was washed twice in deionized water, 
destained with 50% methanol for 30 min at 37°C, 
and dehydrated in 100 μL acetonitrile (ACN) for 
20 min at room temperature. Next, the samples 
were swollen in 50 μL 100 mM NH4HCO3, dehy-
drated a second time, and incubated in 1 µg/50 µL 
trypsin (Promega, Madison, WI, USA) for 30 min 
at 4°C. Then, coverage solution (50 mM NH4HCO3, 
10% ACN, deionized water) was added to the sam-
ples and incubated for 16 h at 37°C. After removing 
the coverage solution by aspiration, the peptide 
mixtures were extracted with 2.5% trifluoroacetic 
acid (TFA)/90% ACN for 30 min at room tempera-
ture and vacuum dried.
Protein identification
The material was dissolved in 1.5 μL solution 
containing deionized water, 0.1% TFA, and 50% 
ACN after vacuum drying. Then, 0.8 μL of the mix-
ture was loaded onto a MALDI sample target plate 
using 0.5 µL HCCA (5 mg/mL a-Cyano-4-hydro-
xycinnamic acid) matrix, dried at room temperature 
and analyzed using the ABI MALDI-TOF/TOF 
Proteomics Analyzer mass spectrometer (Applied 
Biosystems, USA). The UV laser was operated at 
a 200 Hz repetition rate at a wavelength of 355 nm 
and an accelerated voltage of 20 kV.
Database searching
The experimental MS data were matched to 
a corresponding virtual peptide mass database 
derived from GPS Explorer v 3.6, Mascot, and the 
UniProt database under the taxonomy of Homo 
sapiens. Protein identification was carried out by 
peptide mass fingerprint (PMF) with Mascot soft-
ware (http://www.matrixscience.com). The search 
parameters used in PMF were as follows: species: 
Homo sapiens; enzyme: trypsin; fixed modifica-
tions: carbamidomethylation; variable modifica-
tions: oxidation (M). The gene name, function, and 
Gene Ontology (GO) category of each protein was 
determined with the Mascot v 2.1 protein data-
base search engine and the UniProt Homo sapiens 
protein database.
Western blot analysis
Protein extracts from the serum exosomes of 
5 KD patients with CAA and 5 healthy children 
were separated by SDS-PAGE (11–15% acryla-
mide). After being transferred to PVDF mem-
branes and blocked overnight, primary antibody 
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was added for 1 h, followed by washing in PBS, ap-
plication of a secondary HRP-conjugated antibody, 
and development using an ECL system (Thermo 
Fisher Scientific). Anti-tetranectin (TN) (1:1000), 
anti-Leucine-rich alpha-2-glycoprotein (LRG1) 
(1:1000), anti-Retinol-binding protein 4 (RBP4) 
(1:1000), and anti-Apolipoprotein A-IV (APOA4) 
(1:1000) were used as primary antibodies. 
Protein categorization
Differentially expressed proteins were classi-
fied using Protein Analysis Through Evolutionary 
Relationships (PANTHER; http://www.pantherdb.
org). PANTHER ontology is a highly controlled 
vocabulary categorized according to molecular 
function, biological process, and protein class. 
Protein network construction 
An interaction map of the differentially ex-
pressed proteins was established using Pathway 
Studio 5.0 (Ariadne Genomics, Rockville, MD, 
USA), a text-mining tool that can construct protein 
interaction networks and pathways. It includes 
pathway components, protein–protein interactions, 
functional classes, proteins, and their cellular pro-
cesses. In this study, the shortest path analysis 
was selected.
Results
Exosome isolation and validation
Microvesicles isolated from the sera of chil-
dren with CAA caused by KD and healthy controls 
were examined by TEM and Western blotting. 
Spherical structures 30–100 nm in diameter were 
observed by TEM (Fig. 1A). It was validated that 
the microvesicles were exosomes through Western 
blot analysis using antibodies against 3 exosomal 
markers: HSP90a, CD63, and Flotillin. The ex-
pression levels of these 3 markers were markedly 
higher in the microvesicle fraction than in the 
serum fraction (Fig. 1B). These results validated 
that the isolated microvesicles were exosomes.
Identification of differential proteins  
between CAA patients and healthy  
controls by proteomic analysis 
Pooled serum exosome proteins from 5 KD 
patients with CAA and 5 healthy controls were 
separated by 2-DE (Fig. 2A–B). After visual review, 
39 differential protein spots with a minimum of 
1.5-fold difference in expression between the two 
groups were selected for MALDI-TOF/TOF MS 
analysis. Differentially expressed proteins were 
picked from gels and identified using MALDI-
A
B
Control CAA
Control
CD63
Flotillin
Ex ExS S
CAA
Figure 1. Characterization of exosomes in serum samples from patients with coronary artery aneurysm (CAA) caused 
by Kawasaki disease and healthy children. A. Morphological characterization of exosomes by transmission electron 
microscopy; B. Molecular characterization of exosomes by Western blotting. Protein extracts prepared from sera (S) 
or exosomes (Ex) were examined using antibodies against exosomal protein markers (CD63, HSP90a, and flotillin).
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TOF/TOF MS. In total, 32 differentially expressed 
proteins (18 up-regulated and 14 down-regulated) 
were successfully identified (Table 1). Some pro-
teins appeared as multiple spots in 2-DE, likely 
due to their isoforms and/or post-translational 
modifications. 
Validation of differential proteins  
by Western blotting
To further confirm the proteomic analysis re-
sults, Western blotting was performed to examine 
the expression levels of APOA4, LRG1, RBP4, and 
TN in protein extracts from the serum exosomes 
of 5 patients with CAA caused by KD and 5 healthy 
controls. The expression levels of APOA4 and 
LRG1 were significantly higher in the CAA group 
than in the control group (Fig. 3). The expression 
levels of RBP4 and TN were significantly lower in 
the CAA group than in the control group (Fig. 3). 
This result was consistent with the results of 
proteomic analysis.
Classification analysis of identified proteins
According to GO cellular functions and pro-
cesses, the proteins were distributed into catego-
ries based on molecular function, biological pro-
cesses, and protein classes using the PANTHER 
classification system (Fig. 4). Most of the identified 
proteins played roles in the metabolic process 
(18.0%) and immune system process (14.0%). 
Other biological processes that the proteins were 
involved in included response to stimulus (13.0%), 
biology regulation (10.0%), and localization (9.0%). 
In terms of protein class, most of the proteins were 
classified as defense/immunity protein (17.0%), 
enzyme modulator (13.0%), or transfer/carrier pro-
tein (11.0%); others belonged to receptor (11%), 
hydrolase (9.0), signaling molecule (8.0%), and oth-
ers. As for molecular function, the most dominant 
function that the identified proteins were involved 
in was catalytic activity (37.0%), followed by en-
zyme regulator activity (18.0%), binding (18.0%), 
receptor activity (16.0%), transporter activity 
(8.0%), and structural molecule activity (3.0%). 
Network modeling of differentially  
expressed proteins
To explore the associations between differen-
tially expressed proteins, a protein network was 
constructed with Pathway Studio 5.0. Complex 
interactions between mitochondrial, nuclear, cyto-
plasmic, and extracellular proteins were present in 
the prediction network (Fig. 5). Further research 
is needed to explore the role of these proteins and 
their interaction pathways in the pathogenesis of 
CAA due to KD.
Discussion
Cardiovascular complications are a major 
cause of morbidity in KD; the primary concern is 
CAA, which develops in 15–25% of untreated chil-
dren [16]. Importantly, there is no specific modality 
to establish a diagnosis, especially in early stages. 
Treatment with a high dose of IVIG is proven to 
be effective in reducing the prevalence of CAA to 
less than 5%. However, about 10% of patients do 
not respond to this treatment, which represents an 
important clinical dilemma owing to the increased 
risk of developing CAA [17]. Therefore, it is criti-
Figure 2. Two-dimensional electrophoresis analysis of 
the proteome of serum exosomes. Gels were visual-
ized by silver staining. Arrows indicate differentially ex-
pressed proteins in Kawasaki disease (KD) patients with 
coronary artery aneurysm (CAA) and healthy controls. 
Spot numbers correspond to the proteins in Table 1. 
A. Healthy children; B. KD patients with CAA.
A
B
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Table 1. Differentially expressed proteins between Kawasaki disease patients with coronary artery  
aneurysm and healthy children.
Spot  
No.*
Protein Accession 
no.
Protein 
MW (Da)
Protein  
pI
CAA/C Sequence 
coverage
Protein 
score
1 Alpha-1-antitrypsin P01009 44280 5.37 1.95588 32% 319
2 Complement C4-B P0C0L5 194216 6.89 1.67713 13% 255
3 Inter-alpha-trypsin inhibitor  
heavy chain H4
Q14624 103536 6.64 2.05879 18% 251
4 Afamin P43652 70963 5.64 1.90293 23% 287
5 Inter-alpha-trypsin inhibitor  
heavy chain H4
Q59FS1 76971 5.72 2.36148 23% 183
6 Complement C4-A P0C0L4 84758 5.33 –1.96522 26% 229
7 Insulin-like growth factor-binding 
protein complex acid labile subunit
Q8TAY0 66735 6.33 1000000 26% 325
8 Alpha-1B-glycoprotein P04217 52479 5.65 3.7226 26% 185
9 Leucine-rich alpha-2-glycoprotein P02750 38382 6.45 2.34081 31% 464
10 Complement C4-B P0C0L5 40795 5.19 1.50231 26% 137
11 Haptoglobin P00738 38868 6.26 8.13111 29% 269
12 Haptoglobin P00738 38868 6.26 3.62451 20% 141
13 Complement C3 P01024 40204 4.79 1.71764 48% 278
14 Apolipoprotein A-IV P06727 45371 5.28 2.06449 27% 158
15 Antithrombin-III P01008 49350 5.95 –1.65022 40% 476
16 CFI protein Q8WW88 44285 8.49 2.18167 7% 74
17 CFI protein Q8WW88 44285 8.49 2.9125 9% 128
18 CD5 antigen-like O43866 39603 5.28 –1.86353 43% 246
19 Adipocyte plasma membrane-
-associated protein
Q9HDC9 46622 5.82 1.63727 26% 230
20 Sex hormone-binding globulin P04278 28876 5.32 –1.75668 46% 392
21 Sex hormone-binding globulin P04278 28876 5.32 –1.57588 35% 88
22 Haptoglobin-related protein P00739 39300 6.67 2.302 20% 156
23 Haptoglobin P00738 39496 6.42 2.93725 28% 76
24 Complement factor H P08603 36506 5.97 1.72789 39% 152
25 Complement factor H-related  
protein 1
Q03591 38766 7.38 –2.13194 29% 130
26 Ig mu chain C region P01871 50117 6.4 –1.7426 21% 136
27 Alpha-2-macroglobulin P01023 71321 5.47 1.87957 7% 115
28 Serum albumin P02768 58513 5.96 –1.80408 40% 244
29 Beta-2-glycoprotein 1 D9IWP9 37485 8.37 –2.1629 28% 221
30 Serotransferrin P02787 37241 6.49 –1.72825 39% 291
31 Clusterin P10909 36997 5.74 –1.7058 14% 162
32 Transthyretin P02766 12789 5.26 –1000000 68% 155
33 Ig kappa chain V-I region Rei P01607 23779 8.75 –1000000 44% 120
34 Ig lambda chain V-IV region Hil P01717 23020 6.69 1000000 32% 103
35 Ig kappa chain C region P01834 23523 5.72 1.59839 42% 159
36 Retinol-binding protein 4 Q5VY30 21287 5.27 –2.64472 33% 130
37 Tetranectin P05452 22951 5.52 –1000000 42% 295
38 Immunoglobulin lambda-like  
polypeptide 5
B9A064 22819 5.79 1.71135 42% 85
39 Ig kappa chain C region P01834 24352 6.99 1000000 39% 118
*Spot numbers correspond to those in Figure 2. MW — molecular weight; pI — isoelectric point; CAA — coronary artery aneurysm; C — control
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cal to understand the molecular pathogenesis of 
CAA in order to improve the effectiveness of 
diagnosis and therapy for CAA caused by KD. 
Protein profiles from patients at specific stages 
can be more accurate in reflecting the status of 
disease progression. 
Figure 3. Western blot analysis showing the expression of TN, APOA4, RBP4, and LRG1 in 5 Kawasaki disease patients 
with coronary artery aneurysm and 5 healthy children.
Figure 4. Classification analysis of differentially expressed proteins identified between Kawasaki disease patients with 
coronary artery aneurysm (CAA) and healthy controls. Categorization was based on information that was obtained 
from the online Protein Analysis Through Evolutionary Relationships (PANTHER) classification system in terms of (A) 
molecular function, (B) biological process, and (C) protein class.
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Figure 5. Protein network of the identified proteins constructed using Pathway Studio 5.0. The differentially expressed 
proteins in Table 1 were imported into Pathway Assist, and an interaction model was generated using the shortest 
path algorithm. The legend of the interaction network is summarized on the right of the figure. Each node represents 
either a protein entity or a control mechanism of the interaction. 
In this study, 2-DE and MALDI-TOF/TOF MS 
were used to analyze proteomic changes in the se-
rum exosomes of patients with CAA caused by KD. 
32 differentially expressed proteins were identified 
in serum exosome samples, offering a spectrum of 
the proteomic changes caused by CAA. The differ-
ential expression of 4 proteins (TN, LRG1, RBP4, 
and APOA4) was then validated by Western blot-
ting. Finally, these differentially expressed proteins 
were analyzed using a bioinformatics approach. The 
majority of differentially expressed proteins were 
involved in the host immune response, inflamma-
tion, apoptotic process, developmental process, 
and biological adhesion process. This largely favors 
molecular diagnosis and therapy for patients with 
CAA caused by KD. 
Tetranectin, a plasminogen kringle 4 binding 
C-type lectin [18], is a plasma protein secreted by 
monocytes, neutrophils, and macrophages. The 
biological function of TN has not been fully elu-
cidated, though it is thought to play an important 
role in the regulation of proteolytic and fibrinolysis 
processes by binding to plasminogen. It is also 
believed to play a critical role in mineralization 
during osteogenesis and in myogenesis during 
embryonic development [19]. Furthermore, TN 
has been implicated as a potential biomarker in 
conditions ranging from cancer to Parkinson’s 
disease [20]. The present results, detected by 
2-DE and confirmed by Western blotting, showed 
that the expression of TN in the CAA samples was 
significantly lower compared to healthy controls. 
Although validation with a larger sample size is 
necessary, these preliminary results have pro-
vided the first indication, according to available 
research, that TN potentially participates in the 
pathogenesis of CAA caused by KD, and that it is 
a potential CAA biomarker. The function and role 
of TN in CAA caused by KD still remains elusive 
and requires further investigation. 
LRG1 is a protein from the leucine-rich repeat 
(LRR) family. LRG1 is expressed during granulo-
cyte differentiation and might play an important 
role in the immune response when the host clears 
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infections. Previous research has shown that LRG1 
is involved in important pathological and biological 
processes, such as cell adhesion, signal transduction, 
and protein–protein interactions [21]. Recently, LRG1 
was found to be elevated in the serum of patients with 
lung cancer, liver cancer, and pancreatic adenocarci-
noma [22, 23]. In the present study, it was found that 
LRG1 was up-regulated in CAA serum exosomes, 
suggesting that it may be involved in the development 
of CAA, and that the immune response to infection 
might contribute to the formation of CAA in KD.
RBP4 functions to deliver retinol to tissues 
[24]. RBP4 has been correlated with cardiometa-
bolic risk in humans and is related to the degree 
of carotid intima–media thickness. Recent studies 
on aortic rings have shown the vasodilatory effect 
of RBP4 results from increased nitric oxide pro-
duction in vascular endothelial cells. In addition, 
decreased levels of RBP4 have been found in men 
during the acute phase of myocardial infarction and 
in patients with familial hyper-cholesterolemia at 
high risk of an ischemic event; this suggests that 
decreased RBP4 levels lead to an increased sus-
ceptibility to ischemic events, and that RBP4 is 
a potential protective factor against cardiovascular 
events [25, 26]. In the present study, for the first 
time, it was shown that RBP4 was down-regulated 
in CAA serum exosomes compared to healthy con-
trols. It seems that the down-regulation of RBP4 
plays a role in the development of CAA due to KD.
APOA4, a 46-kDa glycoprotein, is produced 
primarily in the small intestine and is discharged 
into the mesenteric lymph [27]. It enters the 
plasma compartment as a structural protein of very 
low-density lipoproteins (VLDL), high-density li-
poproteins (HDL), chylomicrons, or in the lipopro-
tein-free fraction [28]. Currently, the physiological 
function of APOA4 is not fully understood. Several 
studies have shown that it plays a role in reverse 
cholesterol transport. Some studies have reported 
that APOA4 has antioxidant and anti-atherogenic 
properties. A meaningful change in the serum 
APOA4 concentration has been found in patients 
with several disorders including renal disease, 
malabsorption syndrome, and chronic pancreati-
tis. In the present study, it was found that APOA4 
was up-regulated in the serum exosome samples 
of patients with CAA. It seems that APOA4 may 
participate in the development of CAA due to KD.
Conclusions
In conclusion, a set of proteins were identified 
that were differentially expressed in CAA serum 
exosomes compared to healthy control samples. 
Of them, TN, RBP4, LRG1, and APOA4 were vali-
dated by Western blotting. Although none of the 
above-mentioned differentially expressed proteins 
is specifically correlated with CAA caused by KD, 
this preliminary study clearly demonstrated that 
the levels of these proteins were significantly 
changed in patients with CAA compared to healthy 
controls. Preliminary results suggest that these 
proteins may participate in the pathogenesis of 
CAA caused by KD. Future studies are necessary 
to elucidate the molecular role and mechanisms of 
these proteins in CAA caused by KD.
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